Zivo Bioscience, Inc. (ZIVO) stock
ZIVOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 1/30
$6.80+0.30 (+4.62%)
Close on Oct 19, 2026Market cap $25.96MP/E –Yield –
Zivo Bioscience operating margin
Operating margin is operating income as a percentage of revenue.
Zivo Bioscience's operating margin for the twelve months ending Sep 30, 2025 was -4045.7%. For fiscal 2024 it was -8498.9%, against -26267.7% the year before. The highest annual figure on record is -1865.7% in fiscal 2011.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -8498.9% | +17768.8 |
| FY2023 | Dec 31, 2023 | -26267.7% | +16510.7 |
| FY2020 | Dec 31, 2020 | -42778.4% | −40912.7 |
| FY2011 | Dec 31, 2011 | -1865.7% | +3043.4 |
| FY2010 | Dec 31, 2010 | -4909.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -1551.8% | +2020.0 |
| Q2 FY2025 | Jun 30, 2025 | -3057.8% | +13014.9 |
| Q4 FY2024 | Dec 31, 2024 | -1773.8% | +11551.5 |
| Q3 FY2024 | Sep 30, 2024 | -7174.7% | +37859.0 |
| Q1 FY2024 | Mar 31, 2024 | -3571.8% | +8458.8 |
| Q4 FY2023 | Dec 31, 2023 | -16072.8% | – |
| Q3 FY2023 | Sep 30, 2023 | -13325.3% | – |
| Q2 FY2023 | Jun 30, 2023 | -45033.7% | – |
| Q1 FY2020 | Mar 31, 2020 | -12030.6% | – |
See a number that looks wrong?